A Phase 3 clinical trial of BO-112 in 2nd-line melanoma
Latest Information Update: 29 Nov 2021
At a glance
- Drugs BO 112 (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Highlight Therapeutics
- 29 Nov 2021 New trial record
- 12 Nov 2021 According to a Highlight Therapeutics media release, initiation of a pivotal Phase 3 study in 2nd-line melanoma is planned in 2022 following discussions with regulatory agencies in the US and Europe